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The importance of bioconjugates within the field of chemistry drives
the need for novel methodologies for their preparation. Well-defined
and stable bioconjugates are easily accessible via the utilization of
unnatural amino acids (UAAs). As such, we have synthesized and
incorporated two new UAAs into green fluorescent protein, and
optimized a novel Cadiot–Chodkiewicz bioconjugation, effectively
expanding the toolbox of chemical reactions that can be employed
in the preparation of bioconjugates.

Bioconjugates represent a class of molecules in which a biomacromolecule is linked to another molecule, typically a probe, a
surface, or a cytotoxic compound.1,2 Protein-based bioconjugates,
in which a protein is the biomolecule, represent an ever-expanding
field of research. Specifically, protein-based bioconjugates are
becoming increasingly popular for ‘‘lab-on-a-chip’’ technologies,
in which a diagnostic protein is immobilized on a surface, as well
as towards the development of novel cancer therapeutics via the
preparation of antibody-drug conjugates.3–5
The methods to generate a bioconjugate range from noncovalent interactions, typically adsorption and encapsulation,
to covalent linkages.6 While a covalent attachment is more
robust, and less easily disrupted in a biological setting, obtaining a degree of specificity during the synthesis has precluded its
widespread application. This is a consequence of often utilizing
reactive residues within the protein of interest. However, there
are typically multiple nucleophilic residues that can react
within the protein.1 The result is a non-specific coupling that
can either disrupt normal protein function, result in improper
orientation of the protein-bioconjugate, or lead to heterogeneous
mixtures of linkages at multiple residues.6 These limitations can
be overcome by site-specifically incorporating UAAs with chemical
functionalities not found in the canonical amino acids.7,8 In
particular, the suppression of the amber (TAG) stop codon via

Department of Chemistry, College of William & Mary, Williamsburg, Virginia,
23187, USA. E-mail: dyoung01@wm.edu
† Electronic supplementary information (ESI) available: Experimental protocols,
bioconjugation optimization and SDS-PAGE analysis. See DOI: 10.1039/c5cc08287k

88 | Chem. Commun., 2016, 52, 88--91

an exogenous amino-acyl tRNA synthetase (aaRS)/tRNA pair
allows a high level of control over the position of the UAA.9
These UAA-containing proteins can then be conjugated to other
molecules via a bioorthogonal reaction that occurs at physiological conditions (pH = 7, 37 1C) with no chance of crossreaction with other biomolecules.10,11
Indeed a variety of bioorthogonal reactions have already been
developed. These include the copper(I)-catalyzed cycloaddition
between azides and terminal alkynes,12–14 the strain-promoted
cycloaddition,15–17 the oxime formation,18–21 and more recently,
the formation of a conjugated diyne via the copper(I)-catalyzed
Glaser–Hay coupling.22 Despite the wide array of bioorthogonal
chemistries available, each possessing advantages and disadvantages, the individual requirements of the bioconjugate help dictate
which reaction may be best to employ. Due to the increasing
application of bioconjugates, the development of novel bioorthogonal reactions (and UAAs with which they can be employed) are at
the forefront of the field.
The Cadiot–Chodkiewicz reaction affords a conjugated diyne via
the reaction of a terminal alkyne and a halo-alkyne (Fig. 1). In the
presence of a copper(I) salt and a monodentate nitrogenous ligand,
usually triethylamine (TEA), the reaction proceeds to form a covalent
linkage in the form of a conjugated diyne in a relatively chemoselective fashion.23,24 Furthermore, the overall reaction is net redox
neutral, as a single copper(I) catalyst goes through a series of
oxidative additions and reductive eliminations with the bromoalkyne and terminal alkyne reactant to yield the conjugated diyne.25
The Cadiot–Chodkiewicz reaction has diverse applications
to many areas of chemistry. It has been utilized in polymerization reactions, such as in the formation of the backbone of a
solid-state polymer crystal, or in the fabrication of polymerized
monolayer assemblies.26,27 Additionally, several acetylenic
natural products exhibiting valuable biological properties can
be obtained via a Cadiot–Chodkiewicz reaction.28
Similar to the Cadiot–Chodkiewicz reaction, the Glaser–Hay
coupling of two terminal alkynes also affords a diyne.29,30 The
reaction brings together two terminal alkynes generate a diyne
linkage; however, it is not redox neutral and has chemoselectivity
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Fig. 1 Cadiot–Chodkiewicz reaction and associated UAAs. (A) Standard
Cadiot–Chodkiewicz reaction employing a copper(I) salt to couple a terminal
alkyne to a haloalkyne, affording an asymmetrical conjugated diyne product.
(B) p-Propargyloxyphenylalanine (1, pPrF), p-ethynylphenylalanine (2, pEtF),
p-bromopropargyloxyphenylalanine (3, pBrPrF), p-bromoethynylphenylalanine (4, pBrEtF) incorporated into GFP-151 for Glaser–Hay and Cadiot–
Chodkiewicz reactions.

issues as nothing differentiates the two terminal alkynes.31 The
reaction involves the addition of a bidentate nitrogenous
ligand, triethylmethylenediamine (TMEDA),32 which lowers
the reaction temperatures and enhances the kinetics of the
reaction. Recently, we demonstrated a bioorthogonal variant of
the Glaser–Hay reaction that can be conducted in an aqueous
setting under physiological conditions.22 Using a terminal alkynecontaining UAA, we were able to demonstrate that the reaction
proceeds to completion within approximately 6 h at 4 1C, with near
quantitative conjugation. As previously mentioned, the Glaser–Hay
coupling of terminal alkynes has a chemoselectivity issue when the
terminal alkynes differ, resulting in the formation of unwanted
homodimers. However, due to the steric bulk of the protein, we
found that the homodimerization of the reaction was mostly
inhibited, leading to primarily the desired protein heterodimer
product. As such we were able to demonstrate that the Glaser–Hay
reaction could be employed as a novel bioorthogonal chemistry,
yielding stable conjugates with well-defined geometries. However,
the reaction was limited by the oxidative damage of the protein due
to the mechanistic cycling of the copper through three different
redox states. As a result, reactions proceeding for longer than 6 h,
resulted in oxidative damage and protein degradation.
A key component of the Glaser–Hay mechanism is the
formation of a copper(II)-hydroxyl intermediate, which has been
shown to produce hydroxyl radicals that are deleterious to living
systems.33 Because the copper(I) of the Cadiot–Chodkiewicz
reaction is not thought to utilize copper(II) intermediates, we
reasoned that the chemistry could be employed in a biological
context to minimize previously observed oxidative damage.
Furthermore, the reaction is highly chemoselective, as the use
of a halo-alkyne minimizes the formation of homodimer side
products by differentiating the two alkynes. Ultimately, this has the
potential to increase the yield of the conjugated protein product.
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Based on these facts and the limitations of the bioorthogonal
Glaser–Hay, we sought to develop a bioorthogonal variant of
the Cadiot–Chodkiewicz reaction that could be conducted in an
aqueous setting and under physiological conditions.
In order to conduct and optimize a Cadiot–Chodkiewicz
bioconjugation, new UAAs harboring a terminal haloalkyne
needed to be synthesized and incorporated into a protein. In
order to probe UAA-dependent effects on the reaction, aliphatic
and aromatic brominated alkynyl UAAs were prepared from
the previously reported protected p-propargyloxyphenylalanine
(pPrF, 1) and the p-ethynylphenylalanine (pEtF, 2) respectively.34,35
Gratifyingly, the well-established bromination of phenylacetylene
using N-bromosuccinamide (NBS) and silver nitrate worked well
for the synthesis of both UAAs in moderate yields.36,37 Following
deprotection, the final UAAs, p-bromo-propargyloxyphenylalanine
(pBrPrF, 3) and p-bromo-ethynylphenylalanine (pBrEtF, 4), were
recovered in overall good yields (67% and 34% respectively) (Fig. 1).
With the pBrPrF and pBrEtF in hand, it was imperative to
incorporate these UAAs into a model protein. Due to both its
fluorescent properties and well-documented prior use in UAA
development technologies, green fluorescent protein (GFP) was
selected as a model system. Specifically, attempts were made to
incorporate newly synthesized UAAs at residue 151 by suppressing
the amber stop codon. Furthermore, our previous work immobilizing GFP revealed that this surface exposed site is ideal for UAA
placement, as the rigidity of the residue helps orient the bioorthogonal functional handle.38 In lieu of undergoing a tedious aaRS
selection process, we hoped to incorporate the brominated UAAs
using the previously described promiscuous pCNF aaRS.39,40
The pCNF aaRS was investigated first to incorporate pBrPrF and
pBrEtF due to their structural similarity to other UAAs that the
pCNF aaRS incorporates.
BL21(DE3) E. coli were co-transformed with a pEVOL–pCNF
plasmid and a pET-GFP-TAG151 plasmid and used to initiate
an expression culture at OD600 0.1 which was grown to an
OD600 0.7. The culture was subsequently centrifuged and the
cell pellet was resuspended in 4 mL of LB broth supplemented
with antibiotics, IPTG, arabinose, and the presence or absence
of a UAA.34 This previously reported expression protocol allowed
for the minimization of the amount of UAA employed, and was
found to be very effective. After 18–20 h at 37 1C, cells were
pelleted and the expressed GFP was purified.
Gratifyingly, the promiscuous pCNF aaRS incorporated both
brominated-UAA variants with a higher fidelity than the simple
terminal alkyne analogs (Fig. 2). As is to be expected, the smaller
pBrEtF UAA, had a higher incorporation than the pBrPrF. We
hypothesize that the 1-bromo-alkyne moiety provides a degree
of hydrophobic character to the UAA, making the interaction
between the amino acid and the hydrophobic binding pocket of
the aaRS more favourable.
With both brominated alkyne UAAs in hand, it was feasible to
develop a bioorthogonal Cadiot–Chodkiewicz reaction. Initial
studies employed the pBrPrF-containing GFP variant, to mimic
previous Glaser–Hay pPrF-GFP studies and provide an effective
comparison. The Cadiot–Chodkiewicz reaction was carried out
in PBS (pH = 7) using copper iodide and triethylamine (TEA)

Chem. Commun., 2016, 52, 88--91 | 89

View Article Online

Published on 21 October 2015. Downloaded on 4/25/2019 8:43:17 PM.

ChemComm

Fig. 2 Expression of UAA-containing GFP151 using the promiscuous
pCNF aaRS. (A) A stained SDS-PAGE gel indicated successful incorporation
of 3 and 4 over background ( ). A positive control, 1, was also utilized in an
expression. (B) Data for overall incorporation of UAAs via the pCNF aaRS as
measured via absorbance at 280 nm on a nanodrop spectrophotometer
(e/1000 = 20, MW = 26.80 kDa). Data obtained were normalized to the pPrF
UAA (1) to demonstrate the diﬀerence in incorporation eﬃciency over the
previously reported UAA.

(both at a final concentration of 5 mM) in the presence of a
terminal alkyne-containing fluorophore (AlexaFluor 488 alkyne)
at 4 1C for 6 h. The reaction was successful, as fluorescence
could be detected on a denatured SDS-PAGE gel only when
protein and fluorophore were exposed to the CuI/TEA system
(Fig. 3). Even more exciting was the minimal protein degradation
relative to the previously reported Glaser–Hay reaction. Also, due
to the chemoselective nature of the reaction no protein dimerization was detected, and fluorophore dimerization was minimal
and easily removed.
In an attempt to further optimize the reaction, both copper
concentrations and temperatures were varied. A 5 mM working
Cu(I) concentration was found to be ideal, which represents a
marked improvement over the B50 mM concentrations required for
the Glaser–Hay reaction (see ESI†). Previous reports have indicated
that in vivo use of copper-mediated bioorthogonal chemistries
required working concentrations of near 0.1 mM of copper(I)
salt to minimize cytotoxicity.10,41 Thus, the minimized copper concentrations help bring bioorthogonal conjugated diyne chemistry
into the range of in vivo use. These copper concentrations also had
no impact on GFP fluorescence as determined by control reactions.
Additionally, the optimal temperature profile for the reaction was
also investigated. After performing a time course of the reaction at
both 37 1C and 4 1C, we were able to determine very little difference
between either temperature at early time-points. However, as
the reaction was extended to 24 h, greater protein degradation
at 37 1C occurred, most likely due to an increase in the rate of
disproportionation of the Cu(I) catalyst at this temperature,
producing a reactive copper(II) species (Fig. 3 and ESI†). However,
for the 4 1C temperature profile the reaction reached approximately 86% completion in 4 h with minimal protein degradation,
indicating that the bioorthogonal Cadiot–Chodkiewicz reaction
can be performed quickly and in a relatively mild conditions.
Extended times and temperatures resulted in higher yields,
however were accompanied by protein degradation.
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Fig. 3 Bioorthogonal Cadiot–Chodkiewicz reaction. (A) The reaction performed on GFP (0.2 mg mL 1) and AlexaFluor 488 (0.2 mM) in the presence
of 5 mM of CuI and 5 mM TEA at 4 1C. Fluorescence is only observed in the
presence of the CuI/TEA system. (B) Reaction profile at 4 1C over a 24 h time
period. Following analysis via SDS-PAGE, fluorescent imaging, and staining
with coomassie blue, protein levels were normalized to the 0 time point
control. The protein levels indicate minimal to no protein degradation
occurs, even at longer time points. Analysis of coupling efficiency was
determined by calculating the ratio of fluorescence to coomassie staining
for each time point. All reactions were performed in triplicate.

We next sought to explore the eﬀects of an aromatic variant
of the pBrPrF. As such, pBrEtF-GFP151 was expressed, and
subjected to coupling conditions at 4 1C in the presence of an
alkyne fluorophore. Once again a successful conjugation was
observed as determined by SDS-PAGE (see ESI†). Only samples
exposed to the CuI/TEA system exhibited fluorescence while
other controls did not, indicating the fluorescence was not
due to non-specific interactions. Interestingly, the use of an
aromatic containing bromoalkyne appears to be less eﬀective in
the Cadiot–Chodkiewicz reaction than its aliphatic analog.
Next we became interested in exploring how the novel biological
Cadiot–Chodkiewicz conjugation compared to our previously
described Glaser–Hay reactions. In direct comparison, the Cadiot–
Chodkiewicz exhibited far less protein degradation as compared to
the Glaser–Hay versions of either an aliphatic (pPrF) or aromatic
(pEtF) terminal alkyne containing UAAs. Furthermore, the data
indicates that the biological Cadiot–Chodkiewicz reaction proceeds
at a faster rate than the Glaser–Hay, with the aliphatic version
(pBrPrF) of the coupling reaching completion the fastest in 4 h
(Fig. 4). Gratifyingly, these results correlate well with the mechanistic
understanding of both reactions, as the Cadiot–Chodkiewicz
requires a single copper atom, while the Glaser–Hay necessitates
two copper–alkyne conjugates to form the diyne product. Moreover,
the Cu(I)/(III) redox couple of the Cadiot–Chodkiewicz reaction most
likely aids in the minimized protein oxidation relative to the Glaser–
Hay coupling that involves a reactive Cu(II) intermediate. However, it is important to note that the Cadiot–Chodkiewicz
requires brominated UAAs, requiring additional synthetic preparation. In comparison to other bioconjugation techniques,
the Cadiot–Chodkiewicz reaction may be slower; however, it
employs more synthetically accessible UAAs and results in a
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Fig. 4 Comparison of alkyne reactions. Reactions were conducted either
under the described Cadiot–Chodkiewicz conditions or the Glaser–Hay
conditions at 4 1C depending on incorporated UAA. Due to differences in
protein levels resulting from oxidative damage, the ratio of fluorophore
coupling for each data set was normalized to the 24 hour time point in
order to compare coupling trends between reactions.

well-defined linear geometry primed for further reactions. Thus,
the selection of the Cadiot–Chodkiewicz reaction may be dependent on the downstream application and available resources.
Overall, we have accomplished the successful application of the
Cadiot–Chodkiewicz reaction to a biological context. Furthermore,
we have demonstrated that the reaction can be performed with
minimal protein oxidation. Finally, we have showed that the
Cadiot–Chodkiewicz variant requires less harsh copper(I) concentrations, bringing the reaction near the range for in vivo use.
Future work will involve optimization of conditions to increase
the compatibility of the reaction with biological systems, and
extension of the reaction towards in vivo applications.

Notes and references
1 G. T. Hermanson, Bioconjugate Techniques, Academic Press, London,
3rd edn, 1996.
2 K. Lang and J. Chin, Chem. Rev., 2014, 114, 4764–4806.
3 H. Zhu and M. Snyder, Curr. Opin. Chem. Biol., 2003, 7, 55–63.
4 W. Tan, L. Sabet, Y. Li, T. Yu, P. R. Klokkevold, D. T. Wong and
C. M. Ho, Biosens. Bioelectron., 2008, 24, 266–271.
5 D. Brady and J. Jordaan, Biotechnol. Lett., 2009, 31, 1639–1650.
6 F. Rusmini, Z. Zhong and J. Feijen, Biomacromolecules, 2007, 8,
1775–1789.
7 C. Liu, P. Schultz, R. Kornberg, C. Raetz, J. Rothman and J. Thorner,
Annu. Rev. Biochem., 2010, 79, 413–444.
8 T. S. Young and P. G. Schultz, J. Biol. Chem., 2010, 285, 11039–11044.
9 L. Wang and P. G. Schultz, Angew. Chem., Int. Ed., 2004, 44, 34–66.

This journal is © The Royal Society of Chemistry 2016

ChemComm
10 E. Sletten and C. Bertozzi, Angew. Chem., Int. Ed., 2009, 48, 6974–6998.
11 N. J. Agard, J. M. Baskin, J. A. Prescher, A. Lo and C. R. Bertozzi, ACS
Chem. Biol., 2006, 1, 644–648.
12 Q. Wang, T. R. Chan, R. Hilgraf, V. V. Fokin, K. B. Sharpless and
M. G. Finn, J. Am. Chem. Soc., 2003, 125, 3192–3193.
13 V. V. Rostovtsev, L. G. Green, V. V. Fokin and K. B. Sharpless, Angew.
Chem., Int. Ed., 2002, 41, 2596–2599.
14 H. Kolb and K. Sharpless, Drug Discovery Today, 2003, 8, 1128–1137.
15 N. J. Agard, J. A. Prescher and C. R. Bertozzi, J. Am. Chem. Soc., 2004,
126, 15046–15047.
16 J. C. Jewett and C. R. Bertozzi, Chem. Soc. Rev., 2010, 39, 1272–1279.
17 J. Baskin and C. Bertozzi, QSAR Comb. Sci., 2007, 26, 1211–1219.
18 J. Kalia and R. Raines, Curr. Org. Chem., 2010, 14, 138–147.
19 J. Kalia and R. T. Raines, Angew. Chem., Int. Ed., 2008, 47, 7523–7526.
20 B. Hutchins, S. Kazane, K. Staflin, J. Forsyth, B. Felding-Habermann,
V. Smider and P. Schultz, Chem. Biol., 2011, 18, 299–303.
21 S. A. Kazane, J. Y. Axup, C. H. Kim, M. Ciobanu, E. D. Wold,
S. Barluenga, B. A. Hutchins, P. G. Schultz, N. Winssinger and
V. V. Smider, J. Am. Chem. Soc., 2013, 135, 340–346.
22 J. S. Lampkowski, J. K. Villa, T. S. Young and D. D. Young, Angew.
Chem., Int. Ed., 2015, 54, 9343–9346.
23 W. Chodkiewicz, P. Cadiot and A. Willemart, C. R. Hebd. Seances
Acad. Sci., 1957, 245, 2061–2062.
24 J. Montierth, D. DeMario, M. Kurth and N. Schore, Tetrahedron,
1998, 54, 11741–11748.
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